JAK1抑制剂阿布昔替尼治疗激素性玫瑰痤疮：病例系列
JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series.
作者信息
Xu Bingyang, Xu Zining, Ye Shuhong, Sun Hong, Zhao Bin, Wu Na, Wu Jiawen
机构信息
Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
出版信息
Front Med (Lausanne). 2023 Sep 1;10:1239869. doi: 10.3389/fmed.2023.1239869. eCollection 2023.
BACKGROUND
Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.
OBJECTIVE
To observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.
METHODS
Four Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.
RESULTS
Abrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.
CONCLUSION
The JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.
背景
类固醇性酒渣鼻是一种严重的戒断反应，可在面部频繁且过量局部使用类固醇后发生。Janus激酶（JAK）-信号转导子和转录激活子信号通路参与许多生物学过程，可能在类固醇性酒渣鼻的发生发展中起作用。
目的
观察JAK1抑制剂阿布昔替尼治疗类固醇性酒渣鼻的疗效和安全性。
方法
4名中国女性患者口服具有良好安全性的选择性JAK1抑制剂阿布昔替尼，用于治疗类固醇性酒渣鼻。
结果
阿布昔替尼治疗使4名患者的皮肤状况均得到改善，皮肤病生活质量指数评分降低。未报告不适情况，也未观察到不良反应。
结论
JAK1抑制剂阿布昔替尼是一种有前景的类固醇性酒渣鼻潜在治疗药物。
Zotero 插件